Avilex Pharma

Avilex Pharma is a Danish private biotech advancing a pipeline of neuroprotectants targeting PSD-95, a clinically validated target for acute brain injury. The company's lead asset, AVLX-144, has successfully cleared a Phase 1 safety trial and is poised for Phase 2 development in stroke-related indications, supported by venture capital and strategic partnerships. Avilex is also developing next-generation PSD-95 inhibitors and a companion diagnostic PET tracer, positioning it in the high-need, underserved neuroprotection market. The company leverages academic roots from the University of Copenhagen and has secured non-dilutive funding from prestigious grants.

Platform for developing inhibitors of the PSD-95 protein, including small molecules and cyclic peptides, for neuroprotection. Also developing a companion PSD-95 PET tracer biomarker.

Avilex competes in the neuroprotection space, a field known for its difficulty but with limited approved therapies. Direct competitors include other companies developing PSD-95 inhibitors or targeting different nodes in the ischemic cascade. Indirect competition comes from efforts to extend the window for thrombectomy or tPA. Avilex's focus on a clinically validated target and its biomarker strategy may provide a differentiation.